Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.
Researchers have identified two different forms of Parkinson's disease--one that is more toxic than the other--which may explain why symptoms of the neurodegenerative disorder vary so greatly from one patient to another.
In what could be a breakthrough for Alzheimer's and Parkinson's research, U.K. scientists have prevented neurodegeneration in mice using an existing compound to block a pathway associated with brain cell death.
Civitas Therapeutics has scored fresh financing en route to potential late-stage development of an inhaled form of levodopa to treat symptoms of Parkinson's disease. Bay City Capital led the $38 million Series B round, which follows the start of a Phase IIb study for the startup's Parkinson's candidate CVT-301.
Biogen Idec has added another biotech alliance in neurology. Amicus Therapeutics revealed Tuesday that the biotech giant has agreed to fully fund research and development of the company's Parkinson's disease program.
Biogen Idec and Amicus Therapeutics have struck a deal to hunt for novel small molecules to treat Parkinson's disease. The collaboration will focus on finding small molecules that target the lysosomal enzyme glucocerobrosidase (GCase).
Scientists at the U.K.'s Sheffield Institute for Translational Neuroscience (SITraN) have identified new potential disease-modifying compounds that could stop brain cell death and slow the progression of Parkinson's.
Researchers at Johns Hopkins Medicine and the National Cancer Institute have identified a new pathway in Parkinson's disease as well as a potential compound that eases symptoms in mice.
A common ingredient used to fight wrinkles may also have the ability to fight Parkinson's disease. In laboratory tests, researchers found that the chemical, called kinetin, thwarted the death of nerve cells damaged by mutations that cause a hereditary form of Parkinson's.
The U.K. technology transfer organization MRC Technology and the nonprofit Parkinson's UK are partnering in the search for new therapeutic targets to slow, stop or reverse the progression of Parkinson's diseases.